In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA (OBSV), with a price target of $44. The company’s shares closed on Friday at $14.56.
Selvaraju noted:
“Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.83B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban. The current total valuation of $2.2B translates to $44.00 per share, assuming roughly 49M fully-diluted shares outstanding as of end-2019. The fully-diluted shares projected in 12 months includes the exercise of all remaining outstanding options, as well as an equity financing involving the sale of roughly 2M shares in 1H19.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -14.0% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ObsEva SA with a $33.25 average price target.
See today’s analyst top recommended stocks >>
Based on ObsEva SA’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $18.59 million. In comparison, last year the company had a GAAP net loss of $16.99 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
